GEN Exclusives

More »

The Lists

More »
Dec 9, 2013

Top 30 Venture Capital Firms of 2013

Who are the big spenders that help grease the wheels of biotech?

Top 30 Venture Capital Firms of 2013

This year’s list has been expanded to a top 30 in part to include the higher number of firms with funds totaling more than $1.1 billion compared with 2012. [Bobby4237 - Fotolia.com]

  • #10. InterWest Partners

    City (cities) where offices are located: Menlo Park, CA

    Fund size and status: $2.8 billion under management across 10 funds

    Current fund: $650 million IW X Fund, closed 2008

    Current biopharma portfolio companies: Applied Genetic Technologies (AGTC), Alvine Pharmaceuticals, Amplimmune, Arcion Therapeutics, Biomimetic, Carbylan Biosurgery, Cebix, Drais Pharmaceuticals, Eiger Pharmaceuticals, Fluidigm, Integrated Diagnostics (Indi), Lycera, MacroGenics, Ocera Therapeutics, On Demand Therapeutics, PrimeraDx, QuatRx Pharmaceuticals, RadioRx, Sera Prognostics, Tesaro, Transcept Pharmaceuticals, Trius Therapeutics, USDS, Xenon Pharmaceuticals

    Typical investment range: Average per company investment is $10 million to $15 million

    Year established: 1979

  • #9. Atlas Venture

    City (cities) where offices are located: Cambridge, MA

    Fund size and status: More than $3 billion in committed capital across nine funds; about $1 billion in current active assets under management, including $265 million Atlas Venture IX, closed April 2013

    Current biopharma portfolio companies: Achilion Pharmaceuticals, Annovation Biopharma, ARCA Biopharma, Arteaus Therapeutics, Bicycle Therapeutics, CoStim Pharmaceuticals, Egalet, F-star, Harbour Antibodies, Horizon Pharma, Infacare Pharmaceutical, JenaValve, MiRagen Therapeutics, Mnemosyne Pharmaceuticals, Nimbus Discovery, ProtAffin Biotechnologies, RaNA Therapeutics, Rodin Therapeutics, SciClone Pharmaceuticals, Vitae Pharmaceuticals, Zafgen

    Typical investment range: Typical initial investment of $500,000 to $5 million: “Some of our investments are as little as $100K, but we can also follow our portfolio companies through IPO, as in the case of Isilon, where we invested $24M for 24% of the business,” the firm states on its website.

    Year established: 1986

  • #8. Index Ventures

    City (cities) where offices are located: Geneva, London, San Francisco, and St. Helier, Jersey

    Fund size and status: $3.25 billion in total committed capital across mixed and dedicated funds, of which about $1 billion is dedicated to life sciences

    Current fund: $200 million Index Life Sciences VI, closed 2012

    Current biopharma portfolio companies: CoMentis, Egalet, Fast Forward, GenSight Biologics, GlycoVaxyn, Levicept, Minerva, Molecular Partners, Novocure, OncoEthix, Sequenta, Versartis, XO1

    Typical investment range: $50,000 to $25 million per company

    Year established: 1996

  • #7. Canaan Partners

    City (cities) where offices are located: Menlo Park, CA; Westport, CT; New York; Gurgaon, India; Herzliya Pituach, Israel

    Fund size and status: $3.4 billion under management across nine funds

    Current fund: $600 million Canaan Partners IX, closed 2012

    Current biopharma portfolio companies: Adlyfe, ALDEA Pharmaceuticals, Amicus Therapeutics, Apieron, Centocor, Chimerix, Civitas Therapeutics, Cylex, CytomX Therapeutics, Data Sciences International, Dermira, DexCom, Durata Therapeutics, GenVec, Kalidex Pharmaceuticals, Liquidia Technologies, Marinus Pharmaceuticals, Matrix Pharma, Novira Therapeutics, Phylogix, Pozen, Sopherion, Theraclone Sciences, Tobira Therapeutics, VaxInnate, Zalicus (formerly CombinatoRx)

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1987

  • #6. Highland Capital Partners

    City (cities) where offices are located: Cambridge, MA; Menlo Park, CA; Shanghai; London; and Geneva

    Fund size and status: Nearly $3.5 billion under management across 11 funds, the most recently announced being its $25 million Leap Fund™, designed “to support entrepreneurs and companies that are developing breakthrough experiences to solve human scale problems” in sectors that include big data, education, healthcare IT, and security.5 Company has not confirmed a news report that an additional fund, Highland Capital Partners IX L.P., closed last month at $400 million6; Highland disclosed it was seeking to raise that amount in an April 16 filing with the U.S. Securities and Exchange Commission7

    Current biopharma portfolio companies: Aveo Oncology, Hyperion Therapeutics, iPierian, OpGen

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1988

  • #5. Polaris Venture Partners

    City (cities) where offices are located: Waltham, MA; San Francisco; Dublin; Boston office “coming soon”. Also, @dogpatchlabs locations in Cambridge, MA, and Dublin for communities of biotechnology and technology startups

    Fund size and status: $3.5 billion under management across six funds

    Current fund: $375 million Polaris Venture Partners VI, closed 2010

    Current biopharma portfolio companies: Acceleron Pharma, Adimab, Alimera Sciences, Arsanis Biosciences, aTyr Pharma, BIND Biosciences, Calorics Pharmaceuticals, Cerulean Pharma, Fate Therapeutics, Genocea Biosciences, Hydra Biosciences, Ironwood, Kala Pharmaceuticals, Ocular Therapeutix, Promedior, Pulmatrix, Receptos, Selecta Biosciences, Trevena, Visterra, Xtuit Pharmaceuticals

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1996

  • #4. Bessemer Venture Partners

    City (cities) where offices are located: Cambridge, MA; New York; Menlo Park, CA; Sao Paulo, Brazil; Herzliya Pituach, Israel; Mumbai

    Fund size and status: More than $4 billion under management across eight funds

    Current fund: $1.6 billion Bessemer Venture Partners VIII, closed 2011

    Current biopharma portfolio companies: Acceleron Pharma, AffyMax, Allena Pharmaceuticals, Arris Pharmaceuticals, Cerulean Pharma, Insmed, On-Q-ity, Oxagen, Proteon Therapeutics, Verastem

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1911

  • #3. OrbiMed Advisors

    City (cities) where offices are located: New York; San Francisco; Shanghai; Mumbai; Herzliya, Israel

    Fund size and status: More than $8 billion under management in five public funds, as well as private equity funds in North America/Europe, Asia, and Israel; and a Royalty Opportunities Fund launched 2011 to invest in healthcare royalty streams

    Current fund: $735 million OrbiMed Private Investments V, closed October 2013

    Current biopharma portfolio companies: Acceleron Pharma, Adimab, Aerocrine, Affimed, Amarin, Ambit Biosciences, Anthera, arGEN-X, ARMO Biosciences, Arsanis Biosciences, Arteaus, Audentes Therapeutics, Avitide, Bharat Serums and Vaccines, Biodel, BioLineRx, Cardioxyl, cCAM Biotherapeutics, Cerenis Therapeutics, Cleave Biosciences, Durata Therapeutics, Eddingpharm, Good Start Genetics, Igenica, Intercept Pharmaceuticals, Loxo Oncology, MacroGenics, Mirati Therapeutics, Natera, Otic Pharma, Otonomy, OxOnc Development, PharmAbcine, Pieris, Principia Biopharma, RDD Pharma, Receptos, Relypsa, Rempex Pharmaceuticals, Response BioMedical, Roka BioScience, Selecta Biosciences, Singulex, Shasun, Supernus Pharmaceuticals, Waterstone Pharmaceuticals

    Typical investment range: OrbiMed Private Investments V is expected to invest in about 30 portfolio companies, “in amounts generally ranging from $10 million to $50 million”

    Year established: 1989

  • #2. Kleiner Perkins Caufield & Byers

    City (cities) where offices are located: Menlo Park, CA; San Francisco; Beijing; Shanghai

    Fund size and status: More than $7 billion in assets under management across 15 funds

    Current fund: $525 million KPCB 15, closed 2012

    Current biopharma portfolio companies: 3-V Biosciences, Athena Neurosciences, Auxogyn, AwarePoint, BioCryst Pharmaceuticals, Biosite, CardioDx, Cardium Therapeutics, Chiral Quest, Codon Devices, Corixa, Corthera, Crescendo Bioscience, Elcelyx, Emdeon, EntreMed, Epizyme, Essence Healthcare, FivePrime Therapeutics, Focal, Foundation Medicine, Gen-Probe, Genentech, Genomic Health, GenScript, iPierian, ITC, Kindstar Global, Microcide Pharmaceuticals, Navigenics, Neurocrine Biosciences, Nexus Dx, Nodality, Novavax, Oculeve, Onyx Pharmaceuticals, Orexigen, Pacific Biosciences, Pharmacopeia, Pharmacyclics, Rapid Micro Biosystems, Tesaro, Tethys, Trius Therapeutics, True North Therapeutics, Veracyte, Xcellerex, XDx

    Typical investment range: Seed investments typically range from $100,000 to $1 million; early-stage, from $1 million to $10 million; growth-stage, from $10 million to $75 million

    Year established: 1972

  • #1. New Enterprise Associates (NEA)

    City (cities) where offices are located: On November 14, NEA announced opening of its newest office in Cambridge, MA, joining existing offices in Menlo Park, CA; Chevy Chase, MD; Timonium, MD; New York, Chicago; as well as affiliate operations in Beijing; Shanghai; Bangalore; Mumbai.

    Fund size and status: Approximately $13 billion in committed capital across 14 funds

    Current fund: $2.6 billion New Enterprise Associates 14 L.P., closed 2012

    Current biopharma portfolio companies: 3-V Biosciences, Acadia Pharmaceuticals, Aciex, Alimera Sciences, Amicus Therapeutics, Ardelyx, Blend Therapeutics, BrainCells, Cadence Pharmaceuticals, Cardioxyl Pharmaceuticals, Cleave Biosciences, Clovis Oncology, Cydan, Dermira, Edimer Pharmaceuticals, Epizyme, Galera Therapeutics, GlycoMimetics, Hydra Biosciences, Hyperion Therapeutics, Intarcia Therapeutics, Liquidia Technologies, Mersana Therapeutics, Mirna Therapeutics, Nexchem, Novast Holdings, Omthera Pharmaceuticals, Predictive Biosciences, Prosensa, Proteostasis Therapeutics, Psyadon Pharmaceuticals, Ra Pharma, Rhythm Pharmaceuticals, Rigel Pharmaceuticals, Roka Bioscience, Satori Pharmaceuticals, Sunesis Pharmaceuticals, Supernus Pharmaceuticals, Targacept, Tesaro, Theravance, Transcept Pharmaceuticals, Trevena, Vitae Pharmaceuticals, Zyngenia

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1977



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?